Therefore, some non-epithelial or mesenchymal CTCs from cancer patients would be detected on the Parsortix platform but could escape the antigen-dependent enrichment method of the CellSearch® EpCAM assay, and vice versa with epithelial CTCs, such as reflected our spiking experiments with different cell lines expressing different levels of EpCAM. Here, EPCAM is linked to cancer.